Open AccessCurrent Strategies and Potential Prospects of Nanomedicine-Mediated Therapy in Inflammatory Bowel Disease
Author(s) -
Fengqian Chen,
Qi Liu,
Yang Xiong,
Li Xu
Publication year - 2021
Publication title -
international journal of nanomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.245
H-Index - 128
eISSN - 1178-2013
pISSN - 1176-9114
DOI - 10.2147/ijn.s310952
Subject(s) - ulcerative colitis , medicine , inflammatory bowel disease , nanomedicine , crohn's disease , inflammatory bowel diseases , disease , drug delivery , targeted drug delivery , drug , immune system , pharmacology , immunology , nanotechnology , materials science , nanoparticle
Inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis are highly debilitating. IBDs are associated with the imbalance of inflammatory mediators within the inflamed bowel. Conventional drugs for IBD treatment include anti-inflammatory medications and immune suppressants. However, they suffer from a lack of bioavailability and high dose-induced systemic side effects. Nanoparticle (NP)-derived therapy improves therapeutic efficacy and increases targeting specificity. Recent studies have shown that nanomedicines, based on bowel disease's pathophysiology, are a fast-growing field. NPs can prolong the circulation period and reduce side effects by improving drug encapsulation and targeted delivery. Here, this review summarizes various IBD therapies with a focus on NP-derived applications, whereas their challenges and future perspectives have also been discussed.